Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued on Friday.

A number of other analysts also recently issued reports on the company. J P Morgan Chase & Co reaffirmed an “overweight” rating and set a $38.00 price target (up from $32.00) on shares of Enanta Pharmaceuticals in a report on Wednesday. Robert W. Baird lifted their price target on Enanta Pharmaceuticals from $27.00 to $36.00 and gave the stock a “neutral” rating in a report on Tuesday. Zacks Investment Research raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, July 11th. JMP Securities raised Enanta Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $40.00 price target for the company in a report on Tuesday, July 11th. Finally, ValuEngine raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $36.00.

Enanta Pharmaceuticals (NASDAQ:ENTA) traded up 0.64% on Friday, hitting $39.15. The stock had a trading volume of 21,056 shares. Enanta Pharmaceuticals has a 52-week low of $21.00 and a 52-week high of $41.20. The company’s market cap is $746.98 million. The firm’s 50-day moving average is $37.36 and its 200-day moving average is $32.50.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.49) by $0.05. The company had revenue of $7.51 million during the quarter, compared to the consensus estimate of $8.08 million. Enanta Pharmaceuticals had a negative return on equity of 7.74% and a negative net margin of 51.85%. Enanta Pharmaceuticals’s revenue for the quarter was down 46.3% on a year-over-year basis. During the same period in the previous year, the business earned ($0.06) EPS. Equities research analysts anticipate that Enanta Pharmaceuticals will post $0.90 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Enanta Pharmaceuticals, Inc. (ENTA) Raised to “Buy” at BidaskClub” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/08/11/enanta-pharmaceuticals-inc-enta-raised-to-buy-at-bidaskclub.html.

Hedge funds have recently bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in Enanta Pharmaceuticals by 129.7% in the first quarter. Dimensional Fund Advisors LP now owns 413,089 shares of the biotechnology company’s stock worth $12,723,000 after buying an additional 233,265 shares during the period. State Street Corp boosted its stake in Enanta Pharmaceuticals by 31.8% in the first quarter. State Street Corp now owns 748,824 shares of the biotechnology company’s stock worth $23,063,000 after buying an additional 180,586 shares during the period. Candriam Luxembourg S.C.A. boosted its stake in Enanta Pharmaceuticals by 50.8% in the first quarter. Candriam Luxembourg S.C.A. now owns 356,000 shares of the biotechnology company’s stock worth $10,965,000 after buying an additional 120,000 shares during the period. ING Groep NV purchased a new stake in Enanta Pharmaceuticals during the second quarter worth approximately $3,274,000. Finally, Point72 Asset Management L.P. purchased a new stake in Enanta Pharmaceuticals during the first quarter worth approximately $1,731,000. Institutional investors and hedge funds own 65.95% of the company’s stock.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. Its research and development programs are focused on three disease targets: non-alcoholic steatohepatitis (NASH)/ primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings for Enanta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.